ImmunoForge is a company co-founded in 2017 by Dr.Sung-Min Ahn, the head of the Gachon Genetic Science Research Institute at Gachon University Gil Hospital, and Kiho Chang, who has developed new drugs and gained experience in global technology transfer for over 25 years at Dong-A Pharmaceuticals(KRX: 000640), LG Life Sciences(KRX: 051910), and Anguk Pharmaceutical(KRX: 001540), etc., and aims to grow into a world-class company such as Alexion in the field of rare musculoskeletal diseases. ImmunoForge's co-CEO Kiho Chang states that "Based on the recent Series B funding and the U.S. FDA's ODD designation, ImmunoForge will push for global clinical development and global technology transfer of the new drugs, and are aiming to be listed on the KOSDAQ by 2023. ImmunoForge will grow to become a global bio-venture in the field of rare musculoskeletal disease that currently lack appropriate treatments."
| Website | http://www.immunoforge.com |
| Revenue | $5.3 million |
| Employees | View employees |
| Founded | 2017 |
| Phone | +82 70-7721-0755 |
| Industry | Drug Stores & Pharmacies, Health Care, Drug Discovery, Retail, Therapeutics, Biotechnology |
| Competitors | Johnson & Johnson, Roche, Novartis, AbbVie, Merck & Co., Inc., Pfizer, Bristol Myers Squibb, Amgen, Regeneron, Vertex Pharmaceuticals +40 more (view full list) |
| SIC | SIC Code 512 Companies, SIC Code 51 Companies |
| NAICS | NAICS Code 424 Companies, NAICS Code 4242 Companies, NAICS Code 42421 Companies, NAICS Code 42 Companies |
Looking for a particular ImmunoForge employee's phone or email?
ImmunoForge Questions
The ImmunoForge annual revenue was $5.3 million in 2026.
ImmunoForge is based in Seoul, Seoul.
The NAICS codes for ImmunoForge are [424, 4242, 42421, 42].
The SIC codes for ImmunoForge are [512, 51].
